Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Dry Skin Cream, Lotion, and Ointment MarketThe global dry skin cream, lotion, and ointment market is on the cusp of substantial expansion, according to recent market analysis. The industry is ...

Research on the effects of olive oil for eczema is mixed. Some studies suggest it may help relieve inflammation and pain, while others found that it may damage the skin barrier and worsen symptoms.

In a carbon copy of 2023’s results, the 2024 list features AbbVie’s Skyrizi and Rinvoq in the top two spots, followed by yet another immunology giant, Sanofi and Regeneron’s Dupixent ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.